Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Staphylococcus lugdunensis peptidoglycan is a fundamental structural polymer that constitutes the primary component of the bacterial cell wall in this specific coagulase-negative staphylococcus. It is composed of alternating residues of N-acetylglucosamine and N-acetylmuramic acid, which are cross-linked by pentaglycine interpeptide bridges characteristic of the Staphylococcaceae family [1]. This mesh-like scaffold is essential for maintaining the cell's shape and protecting it against high internal osmotic pressure, making it a vital target for antimicrobial therapy [2]. In the context of S. lugdunensis, which is known for its unusual virulence and ability to cause destructive endocarditis, the peptidoglycan layer also serves as a potent pathogen-associated molecular pattern (PAMP) [3]. It is recognized by host pattern recognition receptors such as NOD2, triggering inflammatory responses [4]. Drugs targeting peptidoglycan synthesis, such as vancomycin or oxacillin, disrupt the cross-linking process, leading to bacterial lysis and death [5]. While S. lugdunensis remains susceptible to many cell-wall-active agents, the emergence of resistance mechanisms, such as the acquisition of the mecA gene, poses a significant challenge to effectively targeting this structure [3].
Inhibition of peptidoglycan biosynthesis by binding to D-alanyl-D-alanine precursors (glycopeptides) or inhibiting transpeptidase enzymes (beta-lactams).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcus lugdunensis peptidoglycan (PGN) (PGN).